ReviewThe American journal of case reports2026
CD7 CAR-T Cell as Bridging Therapy for Successful Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory T Lymphoblastic Leukemia/ Lymphoma: A Case Report and Literature Review.
Review in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) carries an exceptionally poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after achieving minimal residual disease (MRD)-negative complete remission (CR) offers the only possibility of long-term remission. However, conventional salvage chemotherapy rarely achieves MRD negativity. Thus, novel bridging strategies to eliminate MRD and enable transplant are urgently needed. CASE REPORT We report the case of a 51-year-old man with T-ALL/LBL who remained MRD-positive despite multiple lines of salvage therapy. As a bridge to transplant, he received donor-derived CD7 chimeric antigen receptor T cells (CAR-T) from his 9/10 HLA-matched son after lymphodepletion. Grade 3 cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed. Bone marrow evaluation on day 15 confirmed morphological complete remission and MRD negativity, which proved sustained. The patient then underwent myeloablative haploidentical HSCT from the same donor. Neutrophil engraftment occurred on day +14 and platelet engraftment on day +45. No acute or chronic graft-versus-host disease developed. Serial monitoring through day +150 demonstrated sustained MRD-negative remission and donor chimerism. CONCLUSIONS Sequential CD7 CAR-T therapy followed by consolidative allo-HSCT is a promising curative approach for high-risk R/R T-ALL/LBL patients, enabling MRD clearance not achievable with chemotherapy alone. This case highlights the feasibility and efficacy of donor-derived CD7 CAR-T as a bridge to transplant, with manageable toxicity. Prospective studies with larger cohorts are needed to further validate this strategy and optimize timing and conditioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.